April 2025

Rising costs of these therapies challenge affordability and access.

Certain antibiotics may have a more significant impact on CAR T-cell efficacy and toxicity.

This alternative to IV infusion reduces patient treatment times and eases providers’ operational burdens.

The FDA approves zanidatamab for HER2-positive biliary cancer, improving treatment options.

Obecabtagene autoleucel improves CAR T-cell therapy for B-cell ALL.

Continuing education supports pharmacy technician career advancement, retention, and skill development.

Delayed pegaspargase reduces hepatotoxicity without affecting outcomes.

Antibody-drug conjugates have revolutionized metastatic breast cancer treatment and classification.

Medically integrated pharmacies improve collaboration, patient care, communication, and therapy management.

A palliative care pharmacist highlights a spectrum of clinical opportunities for patients, caregivers, and clinicians when rounding at the bedside.

The high acceptance rates of these interventions demonstrate the key role in optimizing patient care that clinical oncology pharmacists with access to medical records play.

There are no clearly defined, widely accepted clinical pharmacist metrics.

In business, growth for the sake of growth mirrors the ideology of the cancer cell.

Metrics should empower pharmacists rather than burden them.